Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA.

J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.

PMID:
21383288
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
[PubMed - indexed for MEDLINE]
3.

[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].

Heneberg P.

Klin Onkol. 2011;24(4):256-64. Review. Czech.

PMID:
21905615
[PubMed - indexed for MEDLINE]
4.

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.

Dummer R, Flaherty KT.

Curr Opin Oncol. 2012 Mar;24(2):150-4. doi: 10.1097/CCO.0b013e32834fca92. Review.

PMID:
22316627
[PubMed - indexed for MEDLINE]
5.

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J.

Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. Review.

PMID:
21426297
[PubMed - indexed for MEDLINE]
6.

Vemurafenib: the road to personalized medicine in melanoma.

Amaria RN, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Feb;48(2):109-18. doi: 10.1358/dot.2012.48.2.1745274. Review.

PMID:
22384451
[PubMed - indexed for MEDLINE]
7.

Molecularly targeted therapies for melanoma.

Liu LS, Colegio OR.

Int J Dermatol. 2013 May;52(5):523-30. doi: 10.1111/j.1365-4632.2012.05829.x. Review.

PMID:
23590367
[PubMed - indexed for MEDLINE]
8.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
[PubMed - indexed for MEDLINE]
9.

Mutant BRAF melanomas--dependence and resistance.

Poulikakos PI, Rosen N.

Cancer Cell. 2011 Jan 18;19(1):11-5. doi: 10.1016/j.ccr.2011.01.008. Review.

PMID:
21251612
[PubMed - indexed for MEDLINE]
Free Article
10.

Resistance to BRAF-targeted therapy in melanoma.

Sullivan RJ, Flaherty KT.

Eur J Cancer. 2013 Apr;49(6):1297-304. doi: 10.1016/j.ejca.2012.11.019. Epub 2013 Jan 2. Review.

PMID:
23290787
[PubMed - indexed for MEDLINE]
11.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
[PubMed - indexed for MEDLINE]
12.

Targeting BRAF for patients with melanoma.

Arkenau HT, Kefford R, Long GV.

Br J Cancer. 2011 Feb 1;104(3):392-8. doi: 10.1038/sj.bjc.6606030. Epub 2010 Dec 7. Review.

PMID:
21139585
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
[PubMed - indexed for MEDLINE]
14.

Mechanisms of resistance to RAF inhibitors in melanoma.

Aplin AE, Kaplan FM, Shao Y.

J Invest Dermatol. 2011 Sep;131(9):1817-20. doi: 10.1038/jid.2011.147. Epub 2011 May 19. Review.

PMID:
21593776
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

PLX4032: does it keep its promise for metastatic melanoma treatment?

Livingstone E, Zimmer L, Piel S, Schadendorf D.

Expert Opin Investig Drugs. 2010 Nov;19(11):1439-49. doi: 10.1517/13543784.2010.527945. Epub 2010 Oct 14. Review.

PMID:
20942773
[PubMed - indexed for MEDLINE]
16.

Overcoming metastatic melanoma with BRAF inhibitors.

Hong S, Hong S, Han SB.

Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5. Review.

PMID:
21656352
[PubMed - indexed for MEDLINE]
17.

Vemurafenib: the first drug approved for BRAF-mutant cancer.

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P.

Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Review.

PMID:
23060265
[PubMed - indexed for MEDLINE]
18.

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Vultur A, Villanueva J, Herlyn M.

Clin Cancer Res. 2011 Apr 1;17(7):1658-63. doi: 10.1158/1078-0432.CCR-10-0174. Epub 2011 Mar 29. Review.

PMID:
21447722
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.

Dean E, Lorigan P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1437-48. doi: 10.1586/era.12.124. Review.

PMID:
23249108
[PubMed - indexed for MEDLINE]
20.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk